



### AccuDiag™ Cortisol ELISA Kit

**REF** 6101-15

**IVD** See External Label 8°C 96 Tests

Cortisol ELISA	
Method	Enzyme Linked Immunosorbent Assay
Principle	Competitive ELISA
Detection Range	0-50 µg/dL
Sample	25 µL serum/plasma
Incubation Time	75 minutes
Shelf Life	18 Months from the manufacturing date
Specificity	See Table
Sensitivity	0.37 µg/dL

### PRODUCT FEATURES

- Very easy to use with little training
- Highly specific and consistent Assay
- Provides accurate results quickly
- Reading of results both visually and as absorbance data

### INTENDED USE

The Quantitative Determination of Total Cortisol Concentration in Human Serum or Plasma by a Microplate Enzyme Immunoassay, Colorimetric

### SIGNIFICANCE AND SUMMARY

Cortisol (hydrocortisone, compound F) is the most potent glucocorticoid produced by the human adrenal cortex. As with other adrenal steroids, cortisol is synthesized from cholesterol, through a series of enzymatically mediated steps, by the adrenal cortex.<sup>1,2</sup> The first and rate-limiting step in adrenal steroidogenesis, conversion of cholesterol to pregnenolone, is stimulated by pituitary adrenocorticotrophic hormone (ACTH) which is, in turn, regulated by

hypothalamic corticotropin releasing factor (CRF). ACTH and CRF secretion are inhibited by high cortisol levels. In plasma, the major portion of cortisol is bound with high affinity to corticosteroid-binding globulin (CBG, transcortin), with most of the remainder loosely bound to albumin. Physiologically effective in anti-inflammatory activity and blood pressure maintenance, cortisol is also involved in gluconeogenesis. Cortisol acts through specific intracellular receptors and has effects in numerous other physiologic systems, including immune function, glucose-counter regulation, vascular tone, substrate utilization and bone metabolism.<sup>1,3</sup> Cortisol is excreted primarily in urine in an unbound (free) form.

Cortisol production has an ACTH-dependent circadian rhythm with peak levels in the early morning and a nadir at night. The factors controlling this circadian rhythm are not completely defined. The circadian rhythm of ACTH/cortisol secretion matures gradually during early infancy, and is disrupted in a number of physical and psychological conditions.<sup>4</sup> Furthermore, increased amounts of ACTH and cortisol are secreted independently of the circadian rhythm in response to physical and psychological stress.<sup>4,5</sup>

Elevated cortisol levels and lack of diurnal variation have been identified in patients with Cushing's disease (ACTH hyper secretion).<sup>2,6</sup> Elevated circulating cortisol levels have also been identified in patients with adrenal tumors.<sup>7</sup> Low cortisol levels are found in primary adrenal insufficiency (e.g. adrenal hypoplasia, congenital adrenal hyperplasia, Addison's disease) and in ACTH deficiency.<sup>1,2,8,9</sup> Due to the normal circadian variation of cortisol levels, distinguishing normal and abnormally low cortisol levels can be difficult. Therefore, various tests to evaluate the pituitary-adrenal (ACTH-cortisol) axis, including insulin-induced hypoglycemia, short- and long-term ACTH stimulation, CRF stimulation and artificial blockage of cortisol synthesis with metronome have been performed.<sup>8-10</sup> Cortisol response characteristics for each of these procedures have been reported.


The DAI Cortisol EIA Kit uses a specific monoclonal anti-cortisol antibody, and does not require prior sample extraction of serum or plasma. Cross-reactivity to other naturally-occurring steroids is low.

The employment of several serum references of known cortisol concentration permits construction of a graph of activity and concentration. From comparison to the dose response curve, an unknown specimen's activity can be correlated with cortisol concentration.

### ASSAY PRINCIPLE

#### Competitive Enzyme Immunoassay (TYPE 7):

The essential reagents required for an enzyme immunoassay include antibody, enzyme-antigen conjugate and native antigen upon mixing biotinylated antibody, Enzyme-antigen conjugate and a serum containing the native antigen a competition reaction results between the native antigen and the enzyme-antigen conjugate for a limited number of a limited number of antibody binding sites. The interaction is illustrated by the followed equation:



- Ab<sub>BtN</sub> = Biotinylated Antibody (Constant Quantity)
- Ag = Native Antigen (Variable Quantity)
- <sup>Enz</sup>Ag = Enzyme-antigen Conjugate (Constant Quantity)
- AgAb<sub>BtN</sub> = Antigen-Antibody Complex
- <sup>Enz</sup>Ag Ab<sub>BtN</sub> = Enzyme-antigen Conjugate -Antibody Complex
- K<sub>a</sub> = Rate Constant of Association
- k<sub>a</sub> = Rate Constant of Disassociation
- K = k<sub>a</sub> / k<sub>a</sub> = Equilibrium Constant



A simultaneous reaction between the biotin attached to the antibody and the streptavidin immobilized on the microwell occurs. This effects the separation of the antibody bound fraction after decantation or aspiration.

$AgAb_{Btn} + EnzAgAb_{Btn} + Streptavidin_{CW} \Rightarrow immobilized\ complex$   
Streptavidin<sub>CW</sub> = Streptavidin immobilized on well  
Immobilized complex = sandwich complex bound to the solid surface

The enzyme activity in the antibody-bound fraction is inversely proportional to the native antigen concentration. By utilizing several different serum references of known antigen concentration, a dose response curve can be generated from which the antigen concentration of an unknown can be ascertained.

### REAGENTS

#### Materials provided with the test kit

- A. **Cortisol Calibrators – 1ml/vial:** Six (6) vials of serum reference for Cortisol at concentrations of 0 (A), 1.0 (B), 4.0 (C), 10.0 (D), 20.0 (E), and 50.0 (F) µg/dl. Store at 2-8°C. A preservative has been added.
- B. **Cortisol Enzyme Reagent – 7.0 ml/vial:** One (1) ready to use vial containing Cortisol (Analog)-horseradish peroxides (HRP) conjugate in a protein stabilizing matrix with buffer, red dye, preservative and binding protein inhibitors. Store at 2-8°C.
- C. **Cortisol Biotinylated Reagent – 7.0 ml:** One (1) bottle reagent containing anti-cortisol biotinylated mIgG conjugate in buffer, dye and preservative. Store at 2-8°C.
- D. **Streptavidin Plate – 96 wells:** One 96-well microplate coated with 1.0 µg/ml streptavidin and packaged in an aluminum bag with drying agent. Store at 2-8°C
- E. **Wash Solution Concentrate – 20 ml/vial:** One (1) vial containing a surfactant in buffered saline. A preservative has been added. Store at 2-8°C.
- F. **Substrate A – 7ml/vial:** One (1) vial containing tetramethylbenzidine (TMB) in buffer. Store at 2-8°C.
- G. **Substrate B – 7ml/vial:** One (1) bottle containing hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) in buffer. Store at 2-8°C.
- H. **Stop Solution – 8ml/vial:** One (1) vial containing a strong acid (1N HCl). Store at 2-30°C.
- I. **Product Instructions.**

**Note 1:** Do not use reagents beyond the kit expiration date.

**Note 2:** Opened reagents are stable for sixty (60) days when stored at 2-8°C. Kit and component stability are identified on the label.

**Note 3:** Above reagents are for a single 96-well microplate.

#### Materials required but not provided

1. Pipette capable of delivering 0.025 ml (25µl), 0.050ml (50µl), and 0.100ml (100µl) volumes with a precision of better than 1.5%.
2. Dispenser(s) for repetitive deliveries of 0.050 ml (50µL), 0.100 ml (100 µl) and 0.350ml (350 µl) volumes with a precision of better than 1.5%.
3. Microplate washer or a squeeze bottle (optional).
4. Microplate Reader with 450nm and 620nm wavelength absorbance capability.
5. Absorbent Paper for blotting the microplate wells.
6. Plastic wrap or microplate cover for incubation steps.
7. Vacuum aspirator (optional) for wash steps.
8. Timer.
9. Quality Control Materials.

### PRECAUTIONS

#### For In Vitro Diagnostic Use

#### Not for Internal or External Use in Humans or Animals

All products that contain human serum have been found to be non-reactive for Hepatitis B Surface Antigen, HIV 1&2 and HCV Antibodies by FDA required tests. Since no known test can offer complete assurance that infectious agents are absent, all human serum products should be handled as potentially hazardous and capable of transmitting disease. Good laboratory procedures for handling blood products can be found in the Center for Disease Control / National Institute of Health, "Biosafety in Microbiological and Biomedical Laboratories," 2nd Edition, 1988, HHS Publication No. (CDC) 88-8395.

**Safe Disposal of kit components must be according to local regulatory and statutory requirement.**

### SPECIMEN COLLECTION & PREPARATION

The specimens shall be blood; serum or plasma in type and the usual precautions in the collection of venipuncture samples should be observed. For accurate comparison to established normal values, a fasting morning serum sample should be obtained. The blood should be collected in a plain redtop venipuncture tube without additives or anti-coagulants (for serum) or evacuated tube(s) containing EDTA or heparin. Allow the blood to clot for serum samples. Centrifuge the specimen to separate the serum or plasma from the cells.

**In patients receiving therapy with high biotin doses (i.e. > 5mg/day), no sample should be taken until at least 8 hours after the last biotin administration, preferably overnight to ensure fasting sample.**

Samples may be refrigerated at 2-8°C for a maximum period of five (5) days. If the specimen(s) cannot be assayed within this time, the sample(s) may be stored at temperatures of -20°C for up to 30 days. Avoid repetitive freezing and thawing. When assayed in duplicate, 0.050ml of the specimen is required.

### QUALITY CONTROL

Each laboratory should assay controls at levels in the low, normal and high range for monitoring assay performance. These controls should be treated as unknowns and values determined in every test procedure performed. Quality control charts should be maintained to follow the performance of the supplied reagents. Pertinent statistical methods should be employed to ascertain trends. The individual laboratory should set acceptable assay performance limits. In addition, maximum absorbance should be consistent with past experience. Significant deviation from established performance can indicate unnoticed change in experimental conditions or degradation of kit reagents. Fresh reagents should be used to determine the reason for the variations.

### REAGENT PREPARATION

1. **Wash Buffer**  
Dilute contents of Wash solution to 1000ml with distilled or deionized water in a suitable storage container. Diluted reagent can be stored at 2-30°C for up to 60 days.
2. **Working Substrate Solution** – Stable for 1 year.  
Pour the contents of the amber vial labeled Solution 'A' into the clear vial labeled Solution 'B'. Place the yellow cap on the clear vial for easy identification. Mix and label accordingly. Store at 2-30°C.

**Note 1:** Do not use the working substrate if it looks blue.

**Note 2:** Do not use reagents that are contaminated or have bacteria growth.



### ASSAY PROCEDURE

Before proceeding with the assay, bring all reagents, serum references and controls to room temperature (20-27°C). **\*\*Test Procedure should be performed by a skilled individual or trained professional\*\***

1. Format the microplate wells for each serum reference, control and patient specimen to be assayed in duplicate. **Replace any unused microwell strips back into the aluminum bag, seal and store at 2-8°C.**
2. Pipette 0.025 ml (25µl) of the appropriate serum reference, control or specimen into the assigned well.
3. Add 0.050 ml (50µl) of the ready to use Cortisol Enzyme Reagent to all wells).
4. Swirl the microplate gently for 20-30 seconds to mix.
5. Add 0.050 ml (50µl) of Cortisol Biotin Reagent to all wells.
6. Swirl the microplate gently for 20-30 seconds to mix.
7. Cover and incubate for 60 minutes at room temperature.
8. Discard the contents of the microplate by decantation or aspiration. If decanting, blot the plate dry with absorbent paper.
9. Add 350µl of wash buffer (see Reagent Preparation Section), decant (tap and blot) or aspirate. Repeat two (2) additional times for a total of three (3) washes. **An automatic or manual plate washer can be used. Follow the manufacturer's instruction for proper usage. If a squeeze bottle is employed, fill each well by depressing the container (avoiding air bubbles) to dispense the wash. Decant the wash and repeat two (2) additional times.**
10. Add 0.100 ml (100µl) of working substrate solution to all wells (see Reagent Preparation Section). **Always add reagents in the same order to minimize reaction time differences between wells. DO NOT SHAKE THE PLATE AFTER SUBSTRATE ADDITION**
11. Incubate at room temperature for fifteen (15) minutes.
12. Add 0.050ml (50µl) of stop solution to each well and gently mix for 15-20 seconds. **Always add reagents in the same order to minimize reaction time differences between wells**
13. Read the absorbance in each well at 450nm (using a reference wavelength of 620-630nm to minimize well imperfections) in a microplate reader. **The results should be read within thirty (30) minutes of adding the stop solution.**

**Note:** Dilute the samples suspected of concentrations higher than 50 µg/dl 1:5 and 1:10 with cortisol '0' µg/dl patient serum.

### RESULTS

**A dose response curve is used to ascertain the concentration of cortisol in unknown specimens.**


1. Record the absorbance obtained from the printout of the microplate reader as outlined in Example 1.
2. Plot the absorbance for each duplicate serum reference versus the corresponding cortisol concentration in µg/dl on linear graph paper (do not average the duplicates of the serum references before plotting).
3. Connect the points with a best -fit curve.
4. To determine the concentration of cortisol for an unknown, locate the average absorbance of the duplicates for each unknown on the vertical axis of the graph, find the intersecting point on the curve, and read the concentration (in µg/dl ) from the horizontal axis of the graph (the duplicates of the unknown may be averaged as indicated). In the following example, the average absorbance (1.071) intersects the dose response curve at (10.2ng/dl) cortisol concentration (See figure 1).

Note: Computer data reduction software designed for ELISA assays may also be used for the data reduction. If such software should be ascertained.

Sample I.D.	Well Number	Abs (A)	Mean Abs (B)	Value (µg/dl)
Cal A	A1	2.483	2.543	0
	B1	2.575		
Cal B	C1	2.150	2.194	1.0
	D1	2.186		
Cal C	E1	1.573	1.585	4.0
	F1	1.597		
Cal D	G1	1.103	1.084	10
	H1	1.065		
Cal E	A2	0.726	0.725	20
	B2	0.724		
Cal F	C2	0.347	0.350	50
	D2	0.353		
Ctrl 1	E2	1.624	1.617	3.74
	F2	1.611		
Ctrl 2	G2	0.770	0.760	18.57
	H2	0.749		
Patient 1	A3	1.056	1.071	10.24
	B3	1.086		

\*The data presented in Example 1 is for illustration only and **should not** be used in lieu of a standard curve prepared with each assay.

**Figure 1**



### Q.C. PARAMETERS

**In order for the assay results to be considered valid the following criteria should be met:**

1. The absorbance (OD) of calibrator 0 µg/dl should be ≥ 1.8.
2. Four out of six quality control pools should be within the established ranges.

### RISK ANALYSIS

The MSDS and Risk Analysis Form for this product are available on request from Diagnostic Automation Inc.

### ASSAY PERFORMANCE

1. It is important that the time of reaction in each well is held constant for reproducible results.
2. Pipetting of samples should not extend beyond ten (10) minutes to avoid assay drift.



3. Highly lipemic, hemolyzed or grossly contaminated specimen(s) should not be used.
4. If more than one (1) plate is used, it is recommended to repeat the dose response curve.
5. The addition of the substrate solution initiates a kinetic reaction, which is terminated by the addition of the stop solution. Therefore, the substrate and stop solution should be added in the same sequence to eliminate any time-deviation during reaction.
6. Plate readers measure vertically. Do not touch the bottom of the wells.
7. Failure to remove adhering solution adequately in the aspiration or decantation wash step(s) may result in poor replication and spurious results.
8. Use components from the same lot. No intermixing of reagents from different batches.
9. Accurate and precise pipetting, as well as following the exact time and temperature requirements prescribed are essential. Any deviation from DAI IFU yield inaccurate results.
10. All applicable national standards, regulations and laws, including, but not limited to, good laboratory procedures, must be strictly followed to ensure compliance and proper device usage.
11. It is important to calibrate all the equipment e.g. Pipettes, Readers, Washers and/or the automated instruments used with this device, and to perform routine preventative maintenance.

### INTERPRETATION

1. **Measurements and interpretation of results must be performed by a skilled individual or trained professional.**
2. Laboratory results alone are only one aspect for determining patient care and should not be the sole basis for therapy, particularly if the results conflict with other determinants.
3. The reagents for the procedure have been formulated to eliminate maximal interference; however, potential interaction between rare serum specimens and test reagents can cause erroneous results. Heterophilic antibodies often cause these interactions and have been known to be problems for all kinds of immunoassays. (Boscato LM Stuart MC. 'Heterophilic antibodies: a problem for all immunoassays' Clin. Chem 1988;34:27-33). For diagnostic purposes the results from this assay should be used in combination with clinical examination, patient's history and, all other clinical findings.
4. For valid test results, adequate controls and other parameters must be within the listed ranges and assay requirements.
5. If test kits are altered, such as by mixing parts of different kits, which could produce false test results, or if results are incorrectly interpreted, DACC shall have no liability.
6. If computer-controlled data reduction is used to interpret the results of the test, it is imperative that the predicted values for the calibrators fall within 10% of the assigned concentrations.
7. Total serum cortisol values may be dependent upon conditions such as time of the day for sampling or administration of prednisolone or prednisone (structurally related to cortisol). Caution must be exercised while interpreting cortisol levels for patients undergoing therapy with these and other structurally related corticosteroids such as cortisone or corticosterone.

### EXPECTED RANGES OF VALUES

A study of normal adult population was undertaken to determine expected values for the Cortisol EIA Test System. The mean (R) values, standard deviations ( $\sigma$ ) and expected ranges ( $\pm 2\sigma$ ) are presented in Table 1.

**TABLE 1**  
Expected Values for the cortisol EIA Test System (in  $\mu\text{g/dl}$ )

Population	Morning	Afternoon
Adult	5-23 $\mu\text{g/dl}$	3-13 $\mu\text{g/dl}$
Child	3-21 $\mu\text{g/dl}$	3-10 $\mu\text{g/dl}$
Newborn	1-24 $\mu\text{g/dl}$	

**Please note: Normal results may vary from lab to lab.**

It is important to keep in mind that establishment of a range of values which can be expected to be found by a given method for a population of "normal" persons is dependent upon a multiplicity of factors: The specificity of the method, the population tested and the precision of the method in the hands of the analyst. For these reasons each laboratory should depend upon the range of expected values established by the manufacturer only until an in-house range can be determined by the analysts using the method which a population indigenous to the area in which the laboratory is located.

### PERFORMANCE CHARACTERISTICS

#### Precision

The within and between assay precision of the Cortisol Microplate EIA Test System were determined by analyses on three different levels of pooled patient sera. The number (n), mean values (x), standard deviation ( $\sigma$ ) and coefficient of variation (C.V.) for each of these control sera are presented in Table 2 and Table 3.

**TABLE 2**  
Within Assay Precision (Values in  $\mu\text{g/ml}$ )

Sample	N	X	$\sigma$	CV
Low	16	3.4	0.28	8.2%
Normal	16	14.2	0.91	6.4%
High	16	36.5	2.23	6.1%

**TABLE 3**  
Between Assay Precision (Values in  $\mu\text{g/ml}$ )

Sample	N	X	$\sigma$	CV
Low	10	3.1	0.30	9.7%
Normal	10	15.1	1.06	7.0%
High	10	37.4	2.71	7.3%

\* As measured in ten experiments in duplicate over a ten-day period.

#### Sensitivity

The DAI Cortisol Microplate ELISA Test System has a sensitivity of 91.5 pg. This is equivalent to a sample containing a concentration of 0.366  $\mu\text{g/dl}$ . The sensitivity was ascertained by determining the variability of the 0  $\mu\text{g/dl}$  serum calibrator and using the  $2\sigma$  (95% certainty) statistics to calculate the minimum dose.

#### Accuracy

The DAI Cortisol Microplate ELISA Test System was compared with a coated tube radioimmunoassay method. Biological specimens from low, normal and high cortisol level populations were used (The values ranged from 0.4  $\mu\text{g/dl}$  – 95  $\mu\text{g/dl}$ ). The total number of such specimens was 202. The least square regression equation and the correlation coefficient were computed for this Cortisol in comparison with the reference method. The data obtained is displayed in Table 4.



TABLE 4

Method	Mean (x)	Least Square Regression Analysis	Correlation Coefficient
This Method (y)	16.6	$Y=0.228+1.0186(X)$	0.984
Reference (x)	16.8		

Only slight amounts of bias between this method and the reference method are indicated by the closeness of the mean values. The least square regression equation and correlation coefficient indicates excellent method agreement.


### Specificity

The % cross-reactivity of the Cortisol antibody to selected substances was evaluated by adding the interfering substance to a serum matrix at various concentrations. The cross-reactivity was calculated by deriving a ratio between doses of interfering substance to dose of cortisol needed to displace the same amount of labeled analog.

Substance	Cross Reactivity
Cortisol	1.0000
Androstenedione	0.0004
Cortisone	0.2300
Corticosterone	0.1800
11-Deoxycortisol	0.0550
Dexamethasone	0.0001
Progesterone	0.0002
17 α-OH Progesterone	ND
DHEA	ND
Estradiol	ND
Estrone	ND
Danazol	ND
Testosterone	ND

### MANUFACTURER AND BRAND DETAILS

**ISO 13485:2016**



**Diagnostic Automation/Cortez Diagnostics, Inc.**  
21250 Califa Street, Suite 102 and 116,  
Woodland Hills, California 91367 USA

Date Adopted	2022-09
REF 6101-15	AccuDiag™ - Cortisol ELISA
Brand Name	AccuDiag™
<b>EC REP</b>	CEpartner4U, Esdoornlaan 13, 3951 DB Maarn, The Netherlands. <a href="http://www.cepartner4u.eu">www.cepartner4u.eu</a>
Revision Date: 2019-07-16	

### REFERENCES

- Burtis CA, Ashwood ER: Tietz 'Textbook of Clinical Chemistry' 2<sup>nd</sup> Ed. W.B. Saunders Company. Philadelphia, 1994. Pp 1825-27.
- Foster L, Dunn R, 'Single antibody technique for radioimmunoassay of cortisol in unextracted serum or plasma', Clin Chem, 20. 365 (1974).
- Wilson JD, Foster DW, (Editors) Williams Textbook of Endocrinology, 7<sup>th</sup> Ed WB Saunders, Philadelphia (1985).
- Ruder H, et al, "Radioimmunoassay for cortisol in plasma and urine", J Endo and Metab, 35,219 (1972).
- Crapo L, "Cushing's syndrome: A review of diagnostic tests", Metabolism, 28,955-977 (1979).
- Hyams JS, Carey DE: 'Corticosteroids and Growth. 'J of Pediatrics, 113,249-254(1988).
- Kreiger DT, 'Rhythms of ACTH and corticosteroid secretion in health and disease and their experimental modifications; J of Steroid Biochemistry, 6,785-791 (1975).
- Leistee S, Ahonen P, Perheetupa J,'The diagnosis and staging of hypocortisolism in progressing autoimmune adrenalitis', Pediatrics Res, 76,437 (1985).
- Alsevier RN, Gotlin RW, 'Handbook of Endocrine Tests in Adults and Children' 2<sup>nd</sup> Ed Year Book Medical Pub Inc Chicago. 1978.
- Watts NB, Tindall GT, 'Rapid assessment of corticotrophin reserve after pituitary surgery', JAMA, 259,708(1988).